Dementia Medications

  • Anne M. Lipton
  • Cindy D. Marshall
Chapter

Abstract

In this chapter, we discuss proper medication administration and supervision for the patient with dementia. We review various medications, including cognitive enhancers, those which may help symptoms of dementia, those which may worsen such symptoms, and those which are purported to help—but generally don’t. We also include some tips for helping to decide when a medication is beneficial—and when it is not helping and may even be worsening dementia symptoms.

Keywords

Obstructive Sleep Apnea Progressive Supranuclear Palsy Vascular Dementia Family Caregiver Cholinesterase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Farlow MR, Boustani M. Pharmacological treatment of Alzheimer disease and mild cognitive impairment. In: Weiner MF, Lipton AM, editors. The American psychiatric publishing textbook of Alzheimer disease and other dementias. Washington, DC: American Psychiatric Publishing, Inc.; 2009.Google Scholar
  2. 2.
    Volicer L, Simard J. Management of advanced dementia. In: Weiner MF, Lipton AM, editors. The American psychiatric publishing textbook of Alzheimer disease and other dementias. Washington, DC: American Psychiatric Publishing, Inc.; 2009.Google Scholar
  3. 3.
    Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc. 2003;51(7):937–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Cappell J, Herrmann N, Cornish S, Lanctôt KL. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer’s disease. CNS Drugs. 2010;24(11):909–27. doi: 10.2165/11539530-000000000-00000.PubMedCrossRefGoogle Scholar
  5. 5.
    Wimo A, Winblad B, Stoffler A, Wirth Y, Mobius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics. 2003;21(5):327–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalitities with senile plaques and mental test scores in senile dementia. Br Med J. 1978;2(6150):1457–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL. Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits. J Neurochem. 1995;64(2):749–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351:2509–18.PubMedCrossRefGoogle Scholar
  9. 9.
    Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, Pakrasi S, Richardson J, Sanders J, McKeith IG. A comparison of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2005;20(10):938–44.PubMedCrossRefGoogle Scholar
  10. 10.
    Litvinenko IV, Odinak MM, Mogil’naya VI, Emelin AY. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol. 2008;38(9):937–45.PubMedCrossRefGoogle Scholar
  11. 11.
    Grace J, Amick MM, Friedman JH. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry. 2009;80(1):18–23. Epub 2008 Oct 17.PubMedCrossRefGoogle Scholar
  12. 12.
    Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology. 2001;57(3):456–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Winblad B, Poritis N. Memantine in severe dementia: results of the 9 M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14(2):135–46.PubMedCrossRefGoogle Scholar
  14. 14.
    Mobius HJ, Stoffler A. Memantine in vascular dementia. Int Psychogeriatr. 2003;15 Suppl 1:207–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomized controlled trials. Lancet Neurol. 2007;6(9):782–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8. Epub 2009 Jun 10.PubMedCrossRefGoogle Scholar
  18. 18.
    Emre M, Tsolaki M, Bonuccelli U, Destée A, Tolosa E, Kutzelnigg A, Ceballos-Baumann A, Zdravkovic S, Bladström A, Jones R, 11018 Study Investigators. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77. Epub 2010 Aug 20.PubMedCrossRefGoogle Scholar
  19. 19.
    Boxer A, Womack K, Lipton AM, et al. An open label study of memantine treatment in three subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23(3):211–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Cummings JL, Schneider E, Tariot PN, Graham SM, Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67(1):57–63.PubMedCrossRefGoogle Scholar
  22. 22.
    Feldman HH, Schmitt FA, Olin JT, Memantine MEM-MD-02 Study Group. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord. 2006;20(4):263–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Anne M. Lipton
    • 1
  • Cindy D. Marshall
    • 2
  1. 1.Diplomate in NeurologyAmerican Board of Psychiatry and NeurologyBuffalo GroveUSA
  2. 2.Memory Center, Baylor Neuroscience CenterBaylor University Medical CenterDallasUSA

Personalised recommendations